{"id":"NCT01137474","sponsor":"AstraZeneca","briefTitle":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2010-06-04","resultsPosted":"2014-05-01","lastUpdate":"2017-01-26"},"enrollment":2996,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Placebo-matching dapagliflozin","otherNames":[]}],"arms":[{"label":"Dapagliflozin, 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo-matching dapagliflozin","type":"PLACEBO_COMPARATOR"},{"label":"Dapagliflozin, 2. 5 mg","type":"EXPERIMENTAL"},{"label":"Dapagliflozin, 5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12","timeFrame":"From Baseline to Week 12","effectByArm":[{"arm":"Dapagliflozin 10 mg","deltaMin":-10.4,"sd":0.8822},{"arm":"Placebo","deltaMin":-7.34,"sd":0.8812}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":329,"countries":["United States","Canada","Colombia","Czechia","Denmark","Finland","Germany","Hungary","India","Mexico","Peru","Poland","Puerto Rico","Romania","Russia","Spain"]},"refs":{"pmids":["38770818"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3669&filename=MB102073_CSP_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":311},"commonTop":[]}}